Prediction of postchemotherapy ovarian function using markers of ovarian reserve.
暂无分享,去创建一个
Mousumi Banerjee | Daniel McConnell | Daniel F Hayes | M. Banerjee | D. Hayes | D. McConnell | A. Schott | N. | Anne F Schott | N Lynn Henry | Rong Xia | R. Xia | F. | N. L. Henry | Lynn Henry | Anne | Schott | Daniel | HAYESa
[1] P. Ganz,et al. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Nanette Santoro,et al. Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status. , 2003, The Journal of clinical endocrinology and metabolism.
[3] P. Patrizio,et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Gwyn McClelland. Survivors , 1891, The Hospital.
[5] R. Fanchin,et al. Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. , 2003, Human reproduction.
[6] A. DeMichele,et al. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive‐aged breast cancer survivors , 2010, Cancer.
[7] J. Habbema,et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. , 2005, Fertility and sterility.
[8] A. DeMichele,et al. Antral follicle count provides additive information to hormone measures for determining ovarian function in breast cancer survivors. , 2009, Fertility and sterility.
[9] K. Blackwell,et al. A Pilot Study of Predictive Markers of Chemotherapy-Related Amenorrhea Among Premenopausal Women with Early Stage Breast Cancer , 2008, Cancer investigation.
[10] M. Ellis,et al. Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines , 2007 .
[11] S. Singletary,et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] C. Simón,et al. Evaluation of the ovarian reserve in young low responders with normal basal levels of follicle-stimulating hormone using three-dimensional ultrasonography. , 1998, Fertility and sterility.
[13] W. Rocca,et al. Premature menopause or early menopause: long-term health consequences. , 2010, Maturitas.
[14] S. Crawford,et al. Assessing menstrual cycles with urinary hormone assays. , 2003, American journal of physiology. Endocrinology and metabolism.
[15] Richard A. Anderson,et al. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. , 2011, The Journal of clinical endocrinology and metabolism.
[16] P. Goss,et al. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy , 2007, Steroids.
[17] F. Broekmans,et al. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. , 2002, Human reproduction.
[18] M. Ferin,et al. Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy , 2010, Cancer.
[19] J. Griggs,et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] L. Schapira,et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. , 2010, Fertility and sterility.
[21] M. Banerjee,et al. Predictors of recovery of ovarian function during aromatase inhibitor therapy. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] P. Goodwin,et al. Risk of menopause during the first year after breast cancer diagnosis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] C. Hudis,et al. Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. , 2006, Clinical breast cancer.
[24] S. Singletary,et al. Incidence and time course of bleeding after long‐term amenorrhea after breast cancer treatment , 2010, Cancer.